Submitted by Anonymous (not verified) on 27 November 2023 - 13:40
Human medicines European public assessment report (EPAR): Pluvicto, lutetium (177Lu) vipivotide tetraxetan, Prostatic Neoplasms, Castration-Resistant, Date of authorisation: 09/12/2022, Revision: 4, Status: Authorised
Source: